KLRANasdaqPharmaceutical PreparationsFiscal year ends December 31
Kailera Therapeutics, Inc.
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Aug 12, 2026
$11.43+0.18 (+1.60%)
Close on Oct 19, 2026
- Market cap
- $1.17B
- P/E (TTM)
- –
- Dividend yield
- –
Dividends
Kailera Therapeutics has not reported a dividend
No dividend per share appears in Kailera Therapeutics's annual filings since fiscal 2024.